SAB Biotherapeutics SABS Cash Flow Statement (2020-2026)

NASDAQ SABS
$2.91 +0.03 (+1.22%)
As of: Oct 21, 2026 · 1:11 PM EDT
Reported Financials

SAB Biotherapeutics Quarterly Cash Flow Statement

Periods 23 quarters
Latest Jun 2026

SAB Biotherapeutics reported cash from operations of -$9.84M and free cash flow of -$11.43M for the quarter ended Jun 2026, down 37.6% year over year. This cash flow statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-4.06M-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M45.45M-16.86M-18.87M-22.49M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.04M0.04M0.04M0.03M0.02M0.02M0.03M0.02M0.02M0.03M0.02M0.02M0.02M0.03M0.02M0.02M0.02M0.03M0.02M0.02M
Depreciation & Amortization (CF)Dep. & Amort.
0.37M0.62M0.64M0.75M0.89M0.93M0.90M0.90M1.00M0.97M2.00M1.00M0.90M0.76M0.80M0.80M0.70M0.70M0.73M0.80M
Share-based CompensationStock Comp.
0.88M0.65M0.90M0.57M0.58M0.63M0.60M0.64M0.64M1.99M0.62M0.60M1.05M0.67M0.61M0.63M0.80M3.17M5.46M7.25M
Gains from Sales and DivestituresGains Divest
0.01M0.00M12.000.02M-0.06M0.00M
Gains from Investment SecuritiesGains Investment
0.01M0.01M961.00-0.02M0.04M0.01M0.05M
Other non-cash itemsOther Non-Cash
0.00M4.32M-7.81M-1.73M-0.78M-0.07M-0.08M0.36M-0.18M8.13M-5.47M-2.22M-0.01M2.31M-5.04M0.63M-61.60M3.25M0.48M1.11M
Change in Working Capital
Change in ReceivablesChange Receivables
-6.90M-2.20M3.78M-2.17M3.33M-7.39M-4.79M-0.40M-0.36M
Change in Account PayablesChange Payables
-1.40M0.34M0.52M-0.04M0.54M-1.81M-2.23M-0.04M-0.32M-0.11M0.24M-0.05M0.13M0.59M0.68M0.14M0.34M0.32M0.11M0.67M
Change in Accured ExpensesChange Accured Exp.
1.58M0.28M-0.60M-2.00M0.38M-0.32M-1.73M-0.76M-0.63M1.40M-1.58M-0.07M1.86M-1.44M0.58M1.04M-0.29M-0.39M-1.19M1.83M
Change in TaxesChange Taxes
0.09M
Change in Other Operating AssetsOther Assets Change
0.53M1.61M0.37M-0.66M-0.86M0.42M-0.44M-0.21M-0.23M1.41M0.29M-0.69M0.03M0.96M0.29M0.26M-2.13M6.86M0.30M-1.19M
Change in Other Operating LiabilitiesOther Liabilities Change
0.01M-0.10M0.10M2.94M-0.04M-1.27M-0.31M-0.94M-0.26M-0.11M
Other Working Capital ChangesOther WC Changes
-0.51M-1.61M-0.48M0.66M0.86M-0.32M3.38M0.17M0.13M-0.01M-0.01M-0.02M0.00M0.00M0.05M0.00M0.00M0.00M-0.07M-0.16M
Cash from OperationsCash from Ops.
3.80M-4.88M-9.54M-4.45M-7.92M-1.56M-1.61M-4.90M-5.17M-13.45M-10.75M-7.72M-6.29M-9.53M-7.80M-7.15M-13.05M-16.78M-14.27M-9.84M
Investing Activities
Capital ExpendituresCapex
3.23M2.36M1.36M0.61M0.08M0.12M0.02M0.02M0.09M0.07M0.13M0.05M0.10M0.06M0.98M1.59M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.08M0.04M500.00500.00-500.000.00M783.00
Change in Property, Plant and EquipmentChange in PP&E
-3.23M-2.36M-1.28M-0.61M-0.08M-0.12M-0.02M-0.02M-0.04M-0.07M-0.13M-0.05M-0.10M-0.06M500.00500.00-500.00-0.98M-1.58M
Purchase of InvestmentsInvestments Purchased
31.23M0.11M4.80M1.31M0.07M0.05M129.87M12.04M139.26M13.01M
Sale and Maturity of InvestmentsInvestments Sold
3.75M10.69M4.74M5.25M364.0011.27M74.60M9.71M
Change in Acquisitions & DivestmentsChange Acquisitions
Cash from Investing ActivitiesCash from Investing
-3.23M-2.36M-1.28M-0.61M-0.08M-0.12M-0.02M-0.02M-0.04M-0.07M-31.36M11.22M-1.15M9.33M4.67M5.20M-129.87M-1.71M-65.65M-4.88M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
0.05M1.15M0.80M0.80M0.29M3.79M0.36M0.36M0.14M0.29M0.25M0.25M0.65M0.27M0.03M0.31M0.04M0.04M0.04M
Non-Current Debt
-0.05M-1.15M-0.80M-0.80M-0.29M-3.79M-0.36M-0.36M-0.14M-0.29M-0.25M-0.25M-0.65M-0.27M-0.03M-0.31M-0.04M-0.04M-0.04M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.05M-1.15M-0.80M-0.80M-0.29M-3.79M-0.36M-0.36M-0.14M-0.29M-0.25M-0.25M-0.65M-0.27M-0.03M-0.31M-0.04M-0.04M-0.04M
Change in Capital Stock
Common Stock IssuedStock Issued
-117.63M0.01M0.07M1.007.68M0.00M0.00M59.66M0.02M-3.003.09M0.58M
Net Shares Issued and RepurchasedNet Shares Issued
-117.63M0.01M0.07M1.007.68M0.00M0.00M59.66M0.02M-3.003.09M0.58M
Net Equity Issued and RepurchasedNet Equity Issued
-117.63M0.01M0.07M1.007.68M0.00M0.00M59.66M0.02M-3.003.09M0.58M
Other financing activitiesOther financing
-0.17M-0.07M-0.03M-0.05M0.00M0.00M-0.02M-0.01M0.00M
Cash from Financing ActivitiesCash from Financing
-0.05M36.03M-6.32M-0.73M-0.29M8.39M-0.36M-0.36M-0.14M67.64M-0.39M-0.32M-0.67M0.22M-0.17M-0.17M168.69M-0.04M89.92M2.36M
Additional items
Exchange Rate EffectFX Effect
-0.03M0.03M0.05M-0.29M0.04M0.18M-0.04M-0.40M0.01M0.11M
Change in Cash
0.52M28.79M-17.14M-5.79M-8.28M6.71M-1.99M-5.29M-5.35M54.14M-42.53M3.21M-8.07M-0.27M-3.26M-1.95M25.73M-18.92M10.02M-12.25M
Ending Cash Balance
0.67M39.55M22.41M16.62M8.33M15.05M13.06M7.77M2.43M56.57M14.03M17.24M9.17M8.90M5.64M3.69M29.42M10.50M20.52M8.27M
Free Cash FlowFCF
0.57M-7.24M-10.90M-5.06M-8.00M-1.67M-1.63M-4.92M-5.25M-13.51M-10.88M-7.77M-6.39M-9.59M-7.80M-7.15M-13.05M-16.78M-15.25M-11.43M
Net Cash FlowNCF
0.52M28.79M-17.14M-5.79M-8.28M6.71M-1.99M-5.29M-5.35M54.12M-42.50M3.18M-8.12M0.02M-3.30M-2.13M25.77M-18.52M10.00M-12.36M
Interest Paid
0.08M0.07M0.07M0.07M0.15M0.08M0.04M0.06M0.07M0.07M0.08M0.15M0.07M0.07M0.06M0.04M0.06M0.06M0.06M

SAB Biotherapeutics Cash Flow Statement API

Pull SAB Biotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SABS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY